Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
RESEARCH TOOLSreports
Olema Pharmaceuticals (OLMA) Stock Price & Analysis
642 Followers
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.78 - $17.79
Previous Close$14.31
Volume428.57K
Average Volume (3M)966.76K
Market Cap
$800.41M
Enterprise Value$553.65M
Total Cash (Recent Filing)$248.98M
Total Debt (Recent Filing)$2.21M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 06, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding55,933,827
10 Day Avg. Volume1,089,176
30 Day Avg. Volume966,765
Standard Deviation0.29
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.31
Forecast
1Y Price Target
$26.63Price Target Upside86.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Pharmaceuticals Announces Promising Breast Cancer Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical DataDr. Patricia LoRusso of Yale University School of Medicine presented Phase 1 dose expansion data on PF-07248144, noting significant clinical benefit in over 50% of patients.
Combination TherapyThe combination of palazestrant and ribociclib shows an impressive 85% clinical benefit rate, the highest among comparable studies.
Efficacy Across Patient SubsetsEfficacy was consistently seen across both 2L and 3L patients and regardless of ESR1 mutation, indicating broad potential for the treatment.
Bears Say
Data ImmaturityThe immaturity of the dataset with only 11/50 patients having reached 24 weeks means that to have a meaningful comparison of CBR rates, we really need to wait for OLMA’s next data cut.
Dose ReductionsAlmost half of patients required dose reductions and 3 patients discontinued due to an adverse event.
Safety ConcernsThe most frequent Grade 3 or higher treatment-related adverse event was neutropenia.
---
Ownership Overview
48.31% Insiders
12.21% Mutual Funds
11.79% Other Institutional Investors
27.69% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $7.78 and its highest was $17.79 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on May 08, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.539 by -$0.021.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.54.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 55,933,826 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.539. Following the earnings report the stock price went down -9.309%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 8M.
---
Olema Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.63 (86.09% Upside)
$26.63 (86.09% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 526.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.56%
12-Months-Change
Fundamentals
Return on Equity
-48.31%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$26.63
▲(86.09% Upside)
Technical Analysis
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+113.99%
reiterated a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +113.99% per trade.
---